Early evaluation of sunitinib for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms via CT imaging: RECIST 1.1 or Choi Criteria?
Crossref DOI link: https://doi.org/10.1186/s12885-017-3150-7
Published Online: 2017-02-23
Published Print: 2017-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Luo, Yanji
Chen, Jie
Huang, Kun
Lin, Yuan
Chen, Minhu
Xu, Ling
Li, Zi-Ping
Feng, Shi-Ting
Funding for this research was provided by:
National Natural Science Foundation ofChina (CN) (81571750)
Natural Science Foundation of Guangdong Province (2014A030310484, 2014A030310484)